CoChat

KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples

Open access
Loong, Herbert Ho-Fung, Du, Nan, Cheng, Chunyan, Lin, Hanqing, Guo, Jian, Lin, Gen, Li, Mingjiang, Jiang, Tao, Shi, Zhihua, Cui, Yanzhi, Jin, Xianfeng, Yao, Jicheng, Xing, Yutong, Yao, Ming, Wang, Kai, Mok, Tony S. K., Liu, Lunxu · 2020 · Translational Lung Cancer Research
Cited by 54

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: Kirsten rat sarcoma vial oncogene (KRAS) is one of the most prevalent oncogenes in multiple cancer types, but the incidence is different between the Asian and non-Asian populations. The recent development of KRAS G12C targeting drug has shown great promise. It is thus important to understand the genomic landscape of KRAS G12C in a specific population. Methods: Sequencing data of 11,951 tumor samples collected from 11/2016 to 7/2019 from multiple centres in China were analyzed for KRAS mutation status. Concomitant genomic aberrations were further analyzed in tumors with KRAS G12C mutations, which were sequenced with comprehensive cancer panel including over 450 cancer-related genes. Smoking status and its correlation with KRAS were analyzed in 2,235 lung cancer cases within this cohort. Results: KRAS mutations were identified in 1978 (16.6%) patient samples. Specifically, KRAS G12C accounted for 14.5% (n=286) of all KRAS mutations. G12C was most commonly seen in lung cancer (4.3%), followed by colorectal cancer (2.5%) and biliary cancer (2.3%). Almost all patients (99.6%) with G12C mutations had concomitant genomic aberrations. These were most commonly associated with the RAS/RTK pathway including BRAF and PI3KCA mutations. Moreover, KRAS mutation was positively correlated with smoking status in lung adenocarcinomas. Conclusions: The overall incidence of KRAS G12C mutations remains low in the Chinese population. The most common tumor types harboring KRAS G12C mutations are in patients suffering from lung, colorectal and biliary cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/tlcr-20-455

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 54

Metadata

Authors
Loong, H. H.-F., Du, N., Cheng, C., Lin, H., Guo, J., Lin, G., Li, M., Jiang, T., Shi, Z., Cui, Y., Jin, X., Yao, J., Xing, Y., Yao, M., Wang, K., Mok, T. S. K., & Liu, L.
Venue
Translational Lung Cancer Research
Published
2020-10
Volume
9
Issue
5
Pages
1759-1769
ISSN
  • 2218-6751 (ISSN-L)
  • 2226-4477
OpenAlex
W3081154089
Cited by
54
References
14
FWCI
2.16
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. https://app.cochat.ai/papers/10.21037/tlcr-20-455
The paper
Loong, H. H.-F., Du, N., Cheng, C., Lin, H., Guo, J., Lin, G., Li, M., Jiang, T., Shi, Z., Cui, Y., Jin, X., Yao, J., Xing, Y., Yao, M., Wang, K., Mok, T. S. K., & Liu, L. (2020). KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Translational Lung Cancer Research. https://doi.org/10.21037/tlcr-20-455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.